PDCD1 and Hypocalcemia: A combination of ipilimumab and nivolumab has been reported to significantly increase the incidence of renal irAEs to 4.9%.5 Higher dosage or frequency has also been reported by Izzedine et al. to lead to a higher incidence of renal irAEs,8 while in the meta‐analysis of Manohar et al. by meta‐regression, there was no significant impact of dose of PD‐1 inhibitors (both nivolumab and pembrolizumab) on the rates of AKI, apart from a higher incidence of hypocalcemia in patients treated with high‐dose PD‐1 inhibitors.6